New therapies for medullary thyroid carcinoma
PDF (Español (España))
HTML (Español (España))

Keywords

medullary thyroid carcinoma
c-ret proto-oncogene proteins
LOXO-292
BLU-667
cabozantinib
vandetanib

How to Cite

Román-González, A., Mejía, S., & Zapata, M. (2019). New therapies for medullary thyroid carcinoma. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 6(4), 306–310. https://doi.org/10.53853/encr.6.4.549

Abstract

Patients with advanced medullar thyroid carcinoma have limited options. Current approved therapies for this cancer are vandetanib and cabozantinib. However, the non-specific inhibition produces side effects limiting its use in clinical practice. For example, vandetanib may prolongate QT and in rare cases trigger ventricular arrhythmias. Cabozantinib may be associated with hypertension, hand-and-foot syndrome, fistula and gastrointestinal perforation with bleeding.
RET alterations are associated with medullary thyroid carcinoma as well as other types of cancer such as lung cancer. Specific inhibition of this tyrosine kinase by LOXO-292 y BLU-677 is safe and limited only to RET, without inhibition of other tyrosine kinases. Therefore, its clinical use is promising given its excellent clinical responses and infrequent side effects compared to available tyrosine kinase inhibitors.

https://doi.org/10.53853/encr.6.4.549
PDF (Español (España))
HTML (Español (España))

References

1. Rojas L. Cáncer medular de tiroides. En: Builes C, editor. Tratado de Tiroides. Bogotá: Asociación Colombiana De Endocrinología, Diabetes y Metabolismo; 2014. p. 400-10.
2. Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am. 2014;43(2):423-42.
3. Cabanillas ME, McFadden DG, Durante C. Thyroid cancer. Lancet Lond Engl. 2016;388(10061):2783-95.
4. Chala AI, Franco HI, Aguilar CD, Cardona JP. Estudio descriptivo de doce años de cáncer de tiroides, Manizales, Colombia. Rev Colomb Cir. 2010;25(4):276-89.
5. Uricoechea HV, Chaparro JH, Cabrera IM, Delgado VA. Cáncer de Tiroides e Indicaciones de Tiroidectomia. Medicina (Mex). 2015;37(2):109-21.
6. Sánchez G, Gutiérrez C, Valenzuela Á, Tovar JR. Carcinoma diferenciado de tiroides. Rev Colomb Cir. 2014;29:102-9.
7. Castillo JCR, Niño DC, Sánchez EAW, García ME, Camacho PA, Roa JA, et al. Descripción de los hallazgos histopatológicos en la terapia inicial del cáncer de tiroides en un centro de referencia en Bucaramanga, Colombia. Rev Colomb Endocrinol Diabetes Metab. 2017;2(1):40-3.
8. Wandurraga E, Marín L, Natera A, Gómez C, Niño F, Arenas H, et al. Características clínicas, histopatológicas y terapéuticas del cáncer de tiroides en Colombia: serie de 1.096 pacientes. Rev Colomb Endocrinol Diabetes Metab. 2019;6(1):5-12.
9. Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64-71.
10. Milling RV, Grimm D, Krüger M, Grosse J, Kopp S, Bauer J, et al. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension. Int J Mol Sci. 2018;19(10).
11. Jhiang SM. The RET proto-oncogene in human cancers. Oncogene. 2000;19(49):5590-7.
12. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. septiembre de 1985;42(2):581-8.
13. Sabari JK, Siau ED, Drilon A. Targeting RET-rearranged lung cancers with multikinase inhibitors. Oncoscience. 2017;4(3-4):23-4.
14. Waguespack SG, Rich TA, Perrier ND, Jimenez C, Cote GJ. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol. 2011;7(10):596-607.
15. Wells SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid Off J Am Thyroid Assoc. 2015;25(6):567-610.
16. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151-67.
17. BLU-667 Targets RET-Altered Cancers. Cancer Discov. 2018;8(6):OF8.
18. LOXO-292 Reins In RET-Driven Tumors. Cancer Discov. 2018;8(8):904-5.
19. Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, et al. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018;8(7):836-49.
20. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(6):1394-401.
21. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(8):1988-97.
22. Román A, Sierra J, Gutiérrez J, Builes C, Jiménez C. Feocromocitoma-Paraganglioma: revisio?n de tema. Medicina y Laboratorio. 2015;21(5-6):111-30.
23. Markowitz JN, Fancher KM. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor. Pharmacotherapy. 2018;38(3):357-69.
24. Krajewska J, Olczyk T, Jarzab B. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Expert Rev Clin Pharmacol. 2016;9(1):69-79.
25. Frampton JE. Vandetanib: in medullary thyroid cancer. Drugs. 2012;72(10):1423-36.
26. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897-905.
27. Thornton K, Kim G, Maher VE, Chattopadhyay S, Tang S, Moon YJ, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(14):3722-30.
28. Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(2):134-41.
29. Commander H, Whiteside G, Perry C. Vandetanib: first global approval. Drugs. 2011;71(10):1355-65.
30. Hu MI, Taylor M, Wirth L, Zhu V, Doebele R, Lee DH, et al. Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study. :15. [Internet]. blueprintmedicines.com. [citado 1 de noviembre de 2019]. Disponible en:
https://www.blueprintmedicines.com/wp-content/uploads/2019/01/ATA_BLU667_Oral-Presentation-06Oct2018-Final.pdf

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here

Downloads

Download data is not yet available.